Confirm delete?

Bertin Bioreagent
logo
All categories
Contact Us

LY171883

  • Zoom
    LY171883
  • LY171883
Cat No: 70710
Biochemicals - Receptor Pharmacology
Cayman

LY171883 is a selective, potent, orally active antagonist of the leukotriene D4 receptor.{1741} Dissociation constants (KB) for LY171883 on guinea pig ileum and parenchyma are 0.07 and 0.34 µM, respectively.{1741} LY171883 is an inhibitor of phosphodi...

More

This product can only be bought through Cayman Chemical. Please contact us.

Territorial Availability: Available through Bertin Technologies only in France
Synonyms:
  • 1-[2-hydroxy-3-propyl-4-[4-(1H-tetrazol-5-yl)butoxy]phenyl]-ethanone
Correlated keywords:
  • LTD4 receptors antagonists leukotrienes ly-171883 cysLT1
Product Overview:
LY171883 is a selective, potent, orally active antagonist of the leukotriene D4 receptor.{1741} Dissociation constants (KB) for LY171883 on guinea pig ileum and parenchyma are 0.07 and 0.34 µM, respectively.{1741} LY171883 is an inhibitor of phosphodiesterase obtained from human polymorphonuclear leukocytes (IC50 of 22.6 µM) and various guinea pig tissues (IC50s range from 6.9-209 µM).{1741} At a concentration of 50-100 µM, LY171883 binds to the PPARγ nuclear receptor, inducing adipogenesis in cultured NIH3T3 fibroblasts.{1618,1425}
Size 5 mg
Shipping room temp.
CAS Number 88107-10-2
Molecular Formula C16H22N4O3
SMILES CCCc1c(OCCCCc2nnn[nH]2)ccc(C(=O)C)c1O
Molecular Weight 318,4
Formulation A crystalline solid
Purity ≥98%
Custom Code 2907.19
UNSPSC code 12352100

Click here to ask for your quote and get 15% off Cayman's products.

 

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

/ We also advise you

Cross selling for this product : LY171883 There are 3 products.

Search